We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

woensdag 23 augustus 2017

Nature Reviews Clinical Oncology - Table of Contents alert Volume 14 Issue 9

If you are unable to see the message below, click here to view.
Nature Reviews Clinical Oncology

Searching for immunotherapy answers?

Illuminate immunotherapy treatment opportunities from the complex immuno regulation pathways with Caris Molecular Intelligence®. We provide oncologists reliable molecular information to inform immunotherapy treatment decisions using validated assays for MSI, TML and PD-L1 testing in our state-of-the-art laboratory.

Learn more
September 2017 Volume 14 Number 9
Nature Reviews Clinical Oncology cover
2016 2-year Impact Factor 20.693 Journal Metrics 2-year Median 12
In this issue
Research Highlights
News and Views
Also this month
 Featured article:
Integrating liquid biopsies into the management of cancer
Giulia Siravegna, Silvia Marsoni, Salvatore Siena & Alberto Bardelli


Recommend to library
nature.com webcasts

Nature Research Custom presents a webcast on: HCS for Predictive Toxicology and in vitro Pathology Using Simple 3D Microtissues

Date: Wednesday, September 6, 2017
Time: 8AM PDT | 11AM EDT | 4PM BST | 5PM CEST

Duration: 60 minutes with an opportunity to ask questions during the live broadcast! 

Register for FREE

Sponsored by: 
Context: the grey matter of cancer
p519 | doi:10.1038/nrclinonc.2017.131
Full Text | PDF

Comment: Combining drugs and extending treatment — a PFS end point is not sufficient
Bishal Gyawali & Vinay Prasad

Published online: 23 May 2017
p521 | doi:10.1038/nrclinonc.2017.72

In studies investigating the combination of two or more anticancer drugs that are already approved for independent use, or 'maintenance' regimens, the use of progression-free survival as the end point for approval is inadequate; sequential treatment with the same agents or existing salvage therapies, respectively, might provide an equivalent survival benefit, with lower toxicity, cost, and treatment burden, therefore, the use of an overall survival end point is essential to justify such interventions.
Full Text | PDF | Supplementary information


Genetics: Conditional selection determines the pathways of cancer evolution
p523 | doi:10.1038/nrclinonc.2017.129

Gastrointestinal cancer: Establishing a family tree
Published online: 25 July 2017
p524 | doi:10.1038/nrclinonc.2017.115


Pancreatic Cancer: EGFR inhibition is effective against KRAS-wild-type disease
Published online: 25 July 2017
p524 | doi:10.1038/nrclinonc.2017.119


Immunotherapy: Reality check for nivolumab in advanced-stage melanoma
Published online: 18 July 2017
p525 | doi:10.1038/nrclinonc.2017.112


Prevention: Low-fat diet linked to decline in breast cancer mortality
Published online: 18 July 2017
p526 | doi:10.1038/nrclinonc.2017.110


Prostate cancer: Mutations in ctDNA reflect features of metastatic disease
Published online: 18 July 2017
p526 | doi:10.1038/nrclinonc.2017.111


Breast cancer: Profiling of ultra-low-risk disease
Published online: 18 July 2017
p526 | doi:10.1038/nrclinonc.2017.114




Genetics: BRCA-mutant breast/ovarian cancer revealed | Targeted therapy: ctDNA identified in patients with CUP | Melanoma: Neadjuvant BRAF inhibition enables resection | Haematological cancer: Low-dose CAR T cells are safe and effective

Nature Reviews Clinical Oncology
JOBS of the week
Director, Allogeneic Hematopoietic Stem Cell Transplantation
Princess Margaret Cancer Centre
Physician-Scientist, Oncology / Neoplasia, Assistant or Associate Professor
Brown University
Head of Human Therapeutics
Wisconsin Alumni Research Foundation (WARF)
Associate Director, Center for Immuno-Oncology
Dana-Farber Cancer Institute (DFCI)
Junior Research Group Leader Translational Oncology
German Cancer Research Center (DKFZ).
More Science jobs from
Nature Reviews Clinical Oncology
2nd Edition of International Conferences on Clinical Oncology and Molecular Diagnostics
Dublin, Ireland
More science events from
Haematological cancer: Staging and restaging patients with lymphoma — a better approach?
Vijaya R. Bhatt & James O. Armitage

Published online: 20 June 2017
p527 | doi:10.1038/nrclinonc.2017.81

Response criteria for disease assessment have important therapeutic and prognostic implications in clinical trials and in routine clinical practice. The Lugano classification has been used widely for evaluation of the response of patients with lymphoma to treatment, although the alternative Response Evaluation Criteria In Lymphoma 2017 (RECIL 2017) classification was recently proposed; these criteria are compared herein.
Full Text | PDF

Outcomes research: Integrating PROs into the clinic — overall survival benefit or not, it's worth the trouble
Elisa Sperti & Massimo Di Maio

Published online: 18 July 2017
p529 | doi:10.1038/nrclinonc.2017.109

In 2016, results of an important randomized trial demonstrated that patients undergoing chemotherapy who reported symptoms electronically have a better quality of life than those receiving usual care. Now, a significant survival improvement for patients in the experimental arm of this study has been reported. The emphasis of this survival benefit is 'culturally' positive, promoting the adoption of patient-reported outcomes in clinical practice.
Full Text | PDF

Open for Submissions

npj Precision Oncology is a new open access, online-only, peer-reviewed journal committed to publishing cutting-edge scientific research in all aspects of precision oncology from basic science to translational applications, to clinical medicine.

The journal is part of the Nature Partner Journals series and published in partnership with The Hormel Institute, University of Minnesota.

Explore the benefits of submitting your manuscript.
Integrating liquid biopsies into the management of cancer
Giulia Siravegna, Silvia Marsoni, Salvatore Siena & Alberto Bardelli

Published online: 02 March 2017
p531 | doi:10.1038/nrclinonc.2017.14

Analysis of circulating tumour components using liquid biopsy approaches holds considerable promise to improve the detection and treatment of cancer. In this Review, Alberto Bardelli and colleagues outline how different forms of liquid biopsy, and particularly the assessment of circulating tumour DNA, can be exploited to guide patient care, and discuss the progress made to date in integrating such analyses into the clinic.
Abstract | Full Text | PDF | Supplementary information

Unravelling the biology of SCLC: implications for therapy
Joshua K. Sabari et al.

Published online: 23 May 2017
p549 | doi:10.1038/nrclinonc.2017.71

For three decades, the treatment of small-cell lung cancer (SCLC) has remained essentially unchanged, and patient outcomes remain dismal. In the past 5 years, however, advances in our understanding of the disease, at the molecular level, have resulted in the development of new therapeutic strategies, encompassing immunotherapies and novel molecularly targeted agents. Herein, authors review the breakthroughs that hold the promise to improve SCLC outcomes.
Abstract | Full Text | PDF

Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges
Conor A. Bradley et al.

Published online: 04 April 2017
p562 | doi:10.1038/nrclinonc.2017.40

Patients with c-MET-expressing colorectal or gastrointestinal cancers generally have worse outcomes than those of patients whose tumours have low levels of, or absent c-MET expression. However, c-MET targeted agents have, thus far, failed to show clinical efficacy. In this Review, the authors describe the opportunities and challenges created by the clinical implementation of c-MET targeted therapies.
Abstract | Full Text | PDF | Supplementary information

The changing landscape of clinical trial and approval processes in China
Qing Zhou, Xiao-Yuan Chen, Zhi-Min Yang & Yi-Long Wu

Published online: 14 February 2017
p577 | doi:10.1038/nrclinonc.2017.10

The expansion of research and development of anticancer drugs in China has resulted in considerable delays in the approval of both clinical trials of novel agents, and the marketing approval of these agents once tested. In this Perspective, the authors describe the measures taken by the Chinese FDA to address these challenges in a rapidly developing research environment.
Abstract | Full Text | PDF

nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events
Nature Reviews Clinical Oncology was previously published as Nature Clinical Practice Oncology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature